Early-Stage Non–Small Cell Lung Cancer: Mitigating the Rigors of Therapy

Mark Socinski, MD, considers the challenges surrounding the identification of patients with early-stage non–small cell lung cancer who do not require adjuvant therapy.

Citing the respective costs of adjuvant chemotherapy and immunotherapy in terms of length of treatment, financial burden, and toxicities, Dr Socinski poses circulating tumor DNA as a possible candidate for determining residual disease, and, though admitting its novel status, predicts that this and other methods in development will allow oncologists to focus treatment strategies to include only what is necessary.

Medscape © 2023 WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Early-Stage Non–Small Cell Lung Cancer: Mitigating the Rigors of Therapy - Medscape - Jan 30, 2023.